SOD1 and juvenile Huntington disease: Furthermore, ASOs have presented potential effectiveness in the therapy of Huntington’s disease (HD) by affecting the huntingtin gene (HTT) as the target, in the therapy of amyotrophic lateral sclerosis by influencing SOD1 and C9ORF72 as the targets, and in the therapy of AD by affecting MAPT (tau) as the target (Scoles et al., 2019).